CD274 and Miyoshi myopathy: Interestingly, it has been recently reported that combining a selective HDAC6 inhibitor (ACY-241) with an anti-PD-L1 mAb triggers the effector cell-mediated MM cell killing, supporting their utilization in the clinical studies aimed to restore immune response [137,157,168].